About: Myron J Levin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Myron J Levin Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher (ORCID 0000-0002-7468-106X)

Attributes	Values
rdf:type	Item
description	araştırmacı (tr) wetenschapper (nl) дослідник (uk) researcher (ORCID 0000-0002-7468-106X) (en)
rdfs:label	Myron J Levin (en) Myron J Levin (nl) Myron J. Levin (cs)
skos:prefLabel	Myron J Levin (en) Myron J Levin (nl) Myron J. Levin (cs)
name	Myron J Levin (en) Myron J Levin (nl) Myron J. Levin (cs)
given name	wds:Q92249792-98105762-4b1a-ee36-d809-e473e401f148
given name	Myron
instance of	wds:Q92249792-E1F7EEE0-2972-4E72-BE77-CC7A64036C31
NL CR AUT ID	wds:Q92249792-1AD1F8FD-470F-4FA1-A9F4-BCC632868CF4
instance of	Homo sapiens
NL CR AUT ID	xx0045003
skos:altLabel	Myron Levin (en)
occupation	wds:Q92249792-62142013-26D8-4146-B261-F45B4EF2A0C3
VIAF ID	wds:Q92249792-FAB97807-C63A-4E0E-8574-AB93CAA9850B
family name	wds:Q92249792-e145a684-4077-330d-7aab-a13aee13b2f6
VIAF ID	http://viaf.org/viaf/85584814
occupation	researcher
VIAF ID	85584814
family name	Levin
ORCID iD	wds:Q92249792-A0FE0850-A0FC-4275-A078-64EFAC55BEF0
Dimensions author ID	wds:Q92249792-A3658D0B-E87E-4772-889A-9AE01CA930A0
ORCID iD	https://orcid.org/0000-0002-7468-106X
ORCID iD	0000-0002-7468-106X
Dimensions author ID	010245612617.30
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q92249792
is author of	Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Vaccination against Herpes Zoster and Postherpetic Neuralgia Long-term persistence of zoster vaccine efficacy Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial Prevention of herpes zoster and its painful and debilitating complications The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. A prospective study of the herpes zoster severity of illness Recommendations for the Management of Herpes Zoster Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children Quadrivalent Ann Arbor strain live-attenuated influenza vaccine The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study Decline in Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity with Increasing Age and Boosting with a High‐Dose VZV Vaccine Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study Immunization of HIV-infected children with varicella vaccine Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine Efficacy results of a trial of a herpes simplex vaccine Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines Development of Resistance to Acyclovir during Chronic Infection with the Oka Vaccine Strain of Varicella‐Zoster Virus, in an Immunosuppressed Child Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines Validation of a 3-factor scoring model for the Pittsburgh sleep quality index in older adults Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults The prevention and management of herpes zoster Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women Major depressive disorder and immunity to varicella-zoster virus in the elderly Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella Susceptibility of Herpes Simplex Virus Isolates to Nucleoside Analogues and the Proportion of Nucleoside‐Resistant Variants after Repeated Topical Application of Penciclovir to Recurrent Herpes Labialis Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications Structural Validation of the Hamilton Depression Rating Scale Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy Nectin-1/HveC Mediates herpes simplex virus type 1 entry into primary human sensory neurons and fibroblasts Varicella vaccine in the United States: a decade of prevention and the way forward The rationale for quadrivalent influenza vaccines Vaccination against herpes zoster in developed countries: state of the evidence Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjects Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software